Comparison between angiotensin converting enzyme inhibitors and angiotensin II antagonists;COMPARAISON DES EFFETS DES INHIBITEURS DE L'ENZYME DE CONVERSION ET DES ANTAGONISTES DE L'ANGIOTENSINE II

Therapie

Volumn 53, Issue 3, 1998, Pages 253-270

  Asmar, R ^a   Madonna, O ^b   Brisac, A M ^c   Benetos, A ^d   Laurent, S ^d  

^a Inst Rech Form Cardiovasculaire   (France)

^b JOHNSON AND JOHNSON   (United States)

^c INSERM   (France)

^d HÔPITAL BROUSSAIS   (France)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II receptor antagonists

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KININASE;

ARTERIAL PRESSURE; BLOOD PRESSURE REGULATION; BLOOD VESSEL; BRAIN; CONGESTIVE HEART FAILURE; HEART; HOMEOSTASIS; HUMAN; HYPERTENSION; KIDNEY; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 0031848696     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of A receptors: target for drug research? J Hypertens 1994; 12 (suppl 2): S1-S5.
2. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists. Arch Intern Med 1995; 155: 1361-1368.
3. Menard J. Anthology of the renin-angiotensin system: a one hundred reference approach to angiotensin II antagonists. J Hypertens 1993; 11 (suppl 3): S3-S11.
4. Timmermans P, Wong PC, Chiu AT et al. Angiotensin II receptors and Angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
5. Wexler RR, Carini DJ, Duncia JV et al. Rationale for the chemical development of angiotensin II receptor antagonists. Am J Hypertens 1992; 5: 209S-220S.
6. Burnier M, Waeber B, Brunner H. The advantages of angiotensin II antagonism. J Hypertens 1994; 12 (suppl 2): S7-S15.
7. Luque M, Martin P, Martell N et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996; 14: 799-805.
8. Chiu AT, McCall DE, Price WA et al. Non peptide angiotensin II receptor antagonists: VII. Cellular and biochemical pharmacology of DUP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 711-718.
9. Husain A. The chymase-angiotensin system in human. J Hypertens 1993; 13: 1155-1159.
10. Liao Y, Husain A. The chymase-angiotensin system in humans. Biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995; 11 (suppl. F): 13F-19F.
11. Urata H, Boehm KD, Phillip A et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 12696-1281.
12. De Gasparo M, Husain A, Alexander W et al. Proposed update of angiotensin receptor nomenclature. Hypertension 1995; 5: 924.
13. Chaki S, Inagami T. Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells. Biochem Biophys Res Commun 1992; 182: 388-394.
14. Hanesworth JM, Sardinia MF, Krebs LT, Hall KL, Harding JW. Elucidation of a specific binding site for angiotensin II (3-8) angiotensin IV, in mammalian heart membranes. J Pharmacol Exp Ther 1993; 266: 1036-1042.
15. Wong PC, Hart SD, Duncia JV et al. Non peptide angiotensin II receptor antagonists: studies with DUP 753 and EXP 3174 in dogs. Eur J Pharmacol 1991; 202: 323-330.
16. Wong PC, Price WA, Chiu AT et al. In vivo pharmacology of DUP 753. Am J Hypertens 1991; 4: 288S-298S.
17. Prescott MF, Webb RL, Reidy MA. Angiotensin-converting enzyme inhibitor versus angiotensin II-ATI receptor antagonist. Effect on smooth muscle cell migration and proliferation after ballon catheter injury. Am J Pathol 1991; 139: 1291-1296.
18. Wong PC, Bernard R, Timmermans P. Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function. Hypertension 1992; 19: 663-667.
19. Wong PC, Hart SD, Zaspel AM et al. Functional studies of non peptide angiotensin II receptor subtype-specific ligands: DUP 753 (All-1) and PD 123 177 (All-2). Pharmacol Exp Ther 1990; 255: 584-592.
20. Le Gall S, Feral C, Leymarie P. Renin-angiotensin system of the uterus and ovary in mammalian females. Reprod Nutr Dev: 1993; 33: 185-198.
21. Janiak P, Pillon A, Prost JF, Vilaine JP. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992; 20: 737-745.
22. De Gasparo M, Rogg H, Brink M, Wang L et al. Angiotensin II receptor subtypes and cardiac function. Eur Heart J 1994; 15 (suppl D): 98-103.
23. De Gasparo M, Whitebread S, Levens N et al. Pharmacology of A II receptor subtypes. In: Saez JM, Brownies AC, Capponi A et al. eds. Cellular and Molecular Biology of the Adrenal Cortex (colloque INSERM, Vol 222). London: INSERM/John Libbey Eurotext 1992; 3-17.
24. Dzau VJ, Sasamura H, Hein L. Heterogenecity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 1: S13-S22.
25. Urata H, Healy B, Stewart RW et al. Angiotensin II, forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-890.
26. Benter IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin (1-7) in spontaneously hypertensive rats. Am J Physiol 1995; 269: H313-11319.
27. Benter IF, Diz DI, Ferrario CM. Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Hypertension 1995; 26: 1138-1144.
28. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996; 27: 523-528.
29. Jaiswal N, Diz DI, Chappell MC, Kjosla MC, Ferrario CM. Stimulation of endothelial cell prostaglandin production by angiotensin peptides: characterization of receptors. Hypertension 1992; 19 (suppl. II): II49-II55.
30. Jaiswal N, Tallant EA, Jaiswal RK, Diz DI, Ferrario CM. Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptor involved. J Pharmacol Exp Ther 1993; 265: 664-673.
31. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation 1995; 92: 3424-3430.
32. Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope LM, Lahera V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 1995; 26: 236-243.
33. Cachofeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension 1992; 19: 138-145.
34. Guan H, Cachofeiro V, Pucci ML et al. Nitric oxide and the depressor response to angiotensin blockade in hypertension. Hypertension 1996; 27: 19-24.
35. Kumagai H, Averill DB, Khosla MC, Ferrario CM. Role of nitric oxide and angiotensin II in the regulation of sympathetic nerve activity in spontaneously hypertensive rats. Hypertension 1993; 21: 476-484.
36. Nakamoto H, Ferrario CM., Fuller SB, Robaczewski DL, Winicov E, Dean RH. Angiotensin (1-7) and nitric oxide interaction in renovascular hypertension. Hypertension 1995; 25: 796-802.
37. Brunel P, Agabiti-Rosei E. Effects of angiotensin-converting inhibitors on the heart and vessels in clinical and experimental hypertension. A review. Clin Drug Invest 1996; 12: 226-243.
38. Brunner HR, Nussberger J, Waeber B. Dose-reponse relationships of ACE inhibitors and angiotensin II blockers. Eur Heart J 1994; 15 (suppl D): 123-128.
39. Myers MG. Suggested guidelines for determining the trough-to-peak ratio of antihypertensive drugs. Am J Hypertens 1996; 9: 76S-82S.
40. Zannad F, Matzinger A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996; 9: 633-643.
41. Wong PC, Price WA, Chiu AT et al. Non peptide angiotensin II receptor antagonists: antihypertensive activity in rats of DUP 753, and orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 726-732.
42. Wong PC, Price WA, Chiu AT et al. Hypotensive action of DUP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Non peptide angiotensin II receptor antagonists. Hypertension 1990; 15: 459-468.
43. Dahlof B, Keller SE, Makris L, Goldberg AI, Sweet CS, Lim NY. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578-583.
44. Mallion JM, Bradctreet DC, Makris L et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J Hypertens 1995; 13 (suppl 1): S35-S41.
45. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 1993; 22: 579-584.
46. Linz W, Henning R, Scholkens BA. Role of angiotensin II receptor and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats. J Hypertens 1992; 9 (suppl 6): 400S-401S.
47. Ruzicka M, Yuan B, Harmsen E et al. The renin angiotensin system and volume over-load-induced cardiac hypertrophy in rats. Circulation 1993; 87 (suppl 3): 921-930.
48. Dzau VJ, Pratt RE. Cardiac, vascular and intrarenal renin angiotensin systems in normal physiology and disease. In: Robertson JIS, Nicholls MG. The Renin-angiotensin System, Biochemistry, Physiology, Pathophysiology, Therapeutics. London: Gower Medical 1993; 4201-42011.
49. Cardillo C, Mores N, Motolese M, Folli G. Effects of benazepril on stress testing blood pressure in essential hypertension. Am J Cardiol 1994; 73: 368-373.
50. Lievre M, Gueret P, Gayet C et al. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 1995; 25: 92-97.
51. Dostal DE, Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart-mediation by the ATI receptor. Am j Hypertens 1992; 5: 276-280.
52. Morton JJ, Beattie EC, Mac Pherson F. Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: Lack of relation to vascular structure. J Vasc Res 1992; 29 (suppl 3): 264-269.
53. Laurent S, Vanhoutte P, Cavero I et al. The arterial wall: a new pharmacological and therapeutic target. Fundam Clin Pharmacol 1996; 10: 243-257.
54. Chiu AT, Roscoe WA, Mc Call DE, Timmermans PB. Angiotensin II-1 receptors mediate both vasoconstrictor and hypertrophic responses in rat aortic smooth muscle cells. Receptor 1991; 1 (suppl 3): 133-140.
55. Asmar R, Pannier B, Samtoni JP, Levy B, Safar M. Reversion of cardiac hypertrophy and arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78: 941-950.
56. Asmar R, Iannascoli F, Benetos A, Safar M. Dose optimization study of arterial changes associated with angiotensin converting enzyme inhibition in hypertension.J Hypertens 1992; 10 (suppl. 5): 13-19.
57. Benetos A, Asmar R, Vasmant D et al. Long lasting arterial effects of the ACE inhibitor Ramipril. J Hum Hypertens 1991;5:363-368.
58. Albaladejo P, Bouaziz H, Duriez M et al. Angiotensin converting enzyme inhibition prevents the increase in aortic collagen in rats. Hypertension 1994; 23: 74-82.
59. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition. Hypertension 1991; 18: 132-141.
60. Dohi Y, Criscione L, Pfeiffer K, Luscher TF. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension. Studies in perfused mesenteric resistance arteries. J Cardiovasc Pharmacol 1994; 24: 372-379.
61. Mombouli JV, Nephtali M, Vanhoutte PM. Effects of the converting enzyme inhibitor cilazaprilat on endothelium-dependent responses. Hypertension 1991; 18: II22-II29.
62. Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994; 24: 499-505.
63. Kiowski W, Linder L, Nuesch R, Martina B. Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension 1996; 27: 371-376.
64. Pitt B. Effect of ACE inhibitors on endothelial dysfunction: unanswered questions and implications for further investigations and therapy. Cardiovasc Drugs Ther 1996; 10: 469-473.
65. Kauffman RF, Bean JS, Ziminerman KM et al. Losartan, a nonpeptide angiotensin II (ang.II) receptor antagonist, inhibits neo-intima formation following balloon injury to rat carotid arteries. Life Sciences 1991; 49: 223-228.
66. Levy BI, Benessiano J, Henrion D et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98: 418-425.
67. Ardaillou R. Angiotensin II type II receptor. Does it have a role in the normal or diseased kidney? Nephrol Dial Transplant 1994; 9: 1364-1365.
68. Jover B, Saladini D, Nafrialdi N et al. Effect of losartan and enalapril on renal adaptation to sodium restriction in rat. Am J Physiol 1994; 36: F281-F288.
69. Lafayette RA, Mayer G, Park SK et al. All receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-771.
70. Camargo MJF, Von Lutterotti N, Campbell WG et al. Control of blood pressure and end organ damage in maturing salt loaded stroke prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 1993; 11 (suppl 1): 31-40.
71. Fornes P, Richer C, Vacher E, Pruneval P et al. Losartan's protective effects in stroke prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 1993; 22: 305-313.
72. Bauer JH, Reams GP, Wu Z, Lau-Sieckman A. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Human Hypertens 1995; 9: 237-243.
73. Goldberg MR, Tanaka W, Barchowsky A et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993; 35: 704-713.
74. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-795.
75. Nelson E, MerrilL D, Sweet C et al. Efficacy and safety of oral MK-954 (DUP 753), an angiotensin receptor antagonist, in essential hypertension. J Hypertens 1991; 9 (suppl 6): S468-S469.
76. Weber MA, Byyny RL, Pratt JH et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arc h Intern Med 1995; 155:405-411.
77. Lacourciere Y, Brunner H, Irwin R et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387-1393.
78. Dzau VJ, Hirsch AT. Emerging role of the tissue reninangiotensin systems in congestive heart failure. Eur Heart J 1990; 11:65-71.
79. Dickstein K, Chang P, Willenheimer R et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26: 438-445.
80. Willenheimer R, Dickstein K, Erkarst L et al. Scandinavian losartan pilot mortality study in congestive heart failure. Eur Heart J 1994; 15 (suppl): 35.
81. Klinger G, Jaraunllo N, Ikram H et al. Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure. J Am Coll Cardiol 1997; 29 (suppl. A): 205A (abstract).